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Abstract 37 
Context: Previous studies have shown reduced placental levels of 11-beta-hydroxysteroid 38 
dehydrogenase-type 2 (11βHSD2) in preeclampsia. However, it is not known if the maternal cortisol to 39 
cortisone ratio is predictive of placental complications of pregnancy.   40 
Objective: To determine the relationship between the maternal serum cortisol to cortisone ratio at 41 
different stages of pregnancy and the risk of preeclampsia or fetal growth restriction (FGR).  42 
Design: Women from the Pregnancy Outcome Prediction (POP) study experiencing preeclampsia 43 
(n=194) or FGR (n=185) plus a random sample of healthy controls (n=279) were studied. Steroids were 44 
measured at ~12, ~20, ~28 and ~36 weeks of gestational age (wkGA). Separate analyses were performed 45 
for outcomes with term or preterm delivery. Associations were modelled using logistic regression. 46 
Results: At 28 wkGA, the cortisol to cortisone ratio was negatively associated (odds ratio (OR) per one 47 
standard deviation increase, 95% confidence interval (CI)) with preterm preeclampsia (OR 0.33, 95% CI 48 
0.19-0.57), term preeclampsia (OR 0.61, 95% CI 0.49-0.76) and preterm FGR (OR 0.50, 95% CI 0.29-49 
0.85). At 36 wkGA, the cortisol to cortisone ratio was negatively associated with term preeclampsia (OR 50 
0.42, 95% CI 0.32-0.55) but not term FGR (OR 1.07, 95% CI 0.87-1.31). Associations were not 51 
materially affected by adjustment for maternal characteristics. 52 
Conclusions: A lower maternal serum cortisol to cortisone ratio precedes clinical manifestation of 53 
preeclampsia and preterm FGR by many weeks, despite previous reports of reduced levels of placental 54 
11βHSD2 in these conditions. Our observations implicate enhanced maternal 11βHSD2 activity or 55 
reduced 11βHSD1 activity in the pathophysiology of preeclampsia.  56 
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Precis: A lower maternal cortisol to cortisone ratio precedes clinical diagnosis of preterm and term 57 
preeclampsia. 58 
Abbreviations 59 
11βHSD1- 11-beta-hydroxysteroid dehydrogenase-type 1 60 
11βHSD2 – 11-beta-hydroxysteroid dehydrogenase-type 2 61 
FGR – Fetal growth restriction 62 
FTE – Full time education 63 
MoM – Multiples of the Median 64 
PE – Preeclampsia  65 
POP – Pregnancy Outcome Prediction Study 66 
wkGA – Gestational age in weeks   67 
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Introduction 68 
Preeclampsia (PE) and fetal growth restriction (FGR) are poorly understood conditions of pregnancy 69 
associated with substantial perinatal morbidity and mortality. PE is a disorder of placental origin, 70 
characterized by hypertension and proteinuria that develops during the antenatal or immediate postpartum 71 
period (1). It affects between 2 and 8 percent of pregnancies and is a major cause of direct maternal death 72 
worldwide (2,3). It is often accompanied by FGR, defined as a fetus not reaching its genetically 73 
determined growth potential (4), due to poor placental function. Currently, there are no effective 74 
management options available, apart from delivery, and accurate early prediction of the disease is not 75 
possible. 76 
One marker of placental function which might be affected in PE is the maternal serum cortisol to 77 
cortisone ratio (5). 11-beta-hydroxysteroid dehydrogenase-type 2 (11βHSD2) is a steroid enzyme highly 78 
expressed in the placenta and, by metabolizing cortisol to cortisone, protects the fetus from exposure to 79 
excessive maternal cortisol during pregnancy, while 11-beta-hydroxysteroid dehydrogenase-type 1 80 
(11βHSD1) performs the reverse of 11βHSD2 and reactivates cortisol by converting cortisone to cortisol 81 
(6). Several studies have reported that both PE and FGR are associated with reduced levels of placental 82 
11βHSD2 (7-15) and reduced expression and activity of placental 11βHSD1 have been demonstrated in 83 
cases of small for gestational age (SGA) (16,17). Reduced 11βHSD2 activity would be expected to result 84 
in an increased maternal serum cortisol to cortisone ratio; hence these findings suggest that the maternal 85 
serum cortisol to cortisone ratio may be used as a predictor or marker of disease. A small number of 86 
studies previously addressed this question and paradoxically, reported that women with PE exhibited 87 
lower cortisol to cortisone ratios, suggesting increased maternal 11βHSD2 activity (18-20). However, 88 
these analyses were limited to samples obtained following diagnosis and consisted of studies that had not 89 
included more than 42 cases of confirmed PE and 14 cases of confirmed FGR per study. The aim of the 90 
present study was to investigate the relationship between maternal cortisol and cortisone levels with PE 91 
and FGR, before the onset of disease, using measurements taken at different time points in pregnancy in a 92 
large number of optimally characterized cases and controls.  93 
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Materials and methods 94 
Study design 95 
We utilized a case-cohort design from the Pregnancy Outcome Prediction (POP) study. Details of the  96 
study are provided elsewhere (21), but in brief, it was a prospective cohort study that collected blood, 97 
ultrasound scan and pregnancy outcome data from 4212 nulliparous women at ~12, 20, 28, and 36 weeks 98 
of gestational age (wkGA) between January 14th 2008 and July 31st 2012 (22,23). The case-cohort 99 
included 379 women with cases of PE and FGR and a random sample of the total cohort (n=325) (24). 100 
Out of the 325 women in the random sub-cohort, 279 did not experience any adverse outcome and are 101 
referred to as “healthy”. 102 
 103 
Definitions of outcomes studied. 104 
For this analysis, we studied women with PE or FGR, and divided them into preterm and term sub-groups 105 
based on gestational age at delivery (<37 wkGA and ≥37 wkGA, respectively). PE was diagnosed 106 
according to American College of Obstetricians and Gynecologists (ACOG) 2013 guidelines (25) and the 107 
cases in this analysis included all severe PE at term and non-severe, non-superimposed PE at term, and all 108 
preterm PE. PE cases with preterm delivery were compared with all the women in the sub-cohort who did 109 
not experience PE leading to preterm birth. Term PE cases were compared with women from the sub-110 
cohort who delivered at term without experiencing any type of PE. Preterm FGR was defined as SGA 111 
<10th customized percentile (26) with delivery <37 wkGA. Preterm FGR cases were compared with 112 
women in the sub-cohort who did not deliver a preterm infant with FGR. We excluded preterm cases of 113 
PE from analyses of preterm FGR. FGR at term was defined as severe SGA (birth weight <3rd customized 114 
percentile) or SGA with growth restriction (birth weight <10th customized percentile and reduced growth 115 
velocity of the abdominal circumference on serial ultrasound scans) with delivery ≥37 wkGA. Term FGR 116 
cases were compared with women in the sub-cohort who delivered an infant at term without FGR. In 117 
addition to preterm births, we excluded all types of term PE from analyses of term FGR. Exclusion of 118 
preterm births from the analysis of term outcome was done as women delivering preterm are, necessarily, 119 
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not at risk of complications at term, and the exclusion of PE from the analysis of FGR was made to better 120 
separate the two complications which can be overlapping, especially at preterm GAs.  121 
Outcomes were collected from paper-based hospital records and relevant electronic databases. 122 
Maternal characteristics (age, marital status, ethnicity, smoking, age at leaving full-time education) were 123 
self-reported, except for height and body mass index (BMI), which were measured at the time of 124 
recruitment, and deprivation, which was measured using the Index of Multiple Deprivation 2007 (27), 125 
calculated from the woman’s postcode. 126 
 127 
Steroid measurements 128 
Steroid levels were measured in maternal serum at Metabolon, Inc. (Durham, NC) by non-targeted ultra-129 
high performance liquid chromatography and tandem mass spectrometry. Samples were run in batches of 130 
36 and all batches contained an equal proportion of cases and controls. All samples from a given 131 
participant were run in the same batch. Peaks were quantified using area under the curve of primary MS 132 
ions. Missing values were assumed to be the result of falling below the detection sensitivity, and thus 133 
were imputed with the minimum detection value based on each metabolite. In the entire POP study, where 134 
3,196 samples were successfully processed, only one cortisol value and two cortisone values were 135 
missing (<0.1%). For this analysis, only one woman in the random sub-cohort had a missing cortisol and 136 
cortisone value and this was at 12 wkGA. To adjust for instrument batch effects for each run day, the raw 137 
ion counts for each steroid were divided by the median value for the run day. Internal standards were not 138 
available for all metabolites, so values were not quantified in standard, SI units. Hence, cortisol and 139 
cortisone levels were expressed as multiples of the median (MoMs) (28).  140 
 141 
Statistical Analyses 142 
The cortisol to cortisone ratio for a given sample was generated by dividing the MoM for cortisol by the 143 
MoM for cortisone. Initial descriptive analyses were then conducted by summarizing cortisol, cortisone 144 
and the cortisol to cortisone ratio for each time of measurement (12, 20, 28 and 36 wkGA) in healthy 145 
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pregnancies and women with PE or FGR. Linear regression analyses for cortisone against cortisol were 146 
performed in cases and controls and P values for interaction between these groups were calculated. We 147 
excluded the 36 wkGA measurement from all the analyses of preterm delivery. The MoM values for the 148 
given hormone and their ratio at the given time of sampling were converted to Z scores, using the sub-149 
cohort as the reference. Unadjusted logistic regressions were performed to analyze their associations with 150 
the outcomes. These analyses were repeated adjusting for maternal characteristics (age at recruitment, age 151 
left FTE, height, BMI, smoking status, deprivation, ethnicity, marital status). Missing values were 152 
imputed using the mode for categorical variables and mean for continuous variables.   153 
Time to event analyses (29) were then conducted for term PE from the 36 week measurement 154 
onwards and preterm PE from the 28 wkGA measurement onwards. We studied the whole case-cohort 155 
sample, weighting the non-cases of the comparator group by the inverse of the sampling fraction (30). We 156 
compared the cumulative incidence of PE between women with a cortisol to cortisone ratio in the 1st 157 
decile (using a threshold derived from the random sub-cohort) to women in the 2nd to 10th deciles. 158 
Delivery without PE was considered a competing risk.  159 
Finally, we performed a sensitivity analysis confined to women where it was documented that 160 
they had not received steroids antenatally (either for fetal lung maturation or medical conditions such as 161 
asthma). As the research database only started recording information on whether women had received 162 
steroids to accelerate fetal lung maturation from 27/11/2009 onwards, the majority of women excluded in 163 
the sensitivity analysis were omitted because the data were absent rather than they were documented as 164 
receiving steroids. Where the apparent statistical significance of an association between an outcome and 165 
the cortisol to cortisone ratio differed in the sensitivity analysis, we tested for an interaction between the 166 
ratio and antenatal steroid use to determine if there was a true difference between the groups, or whether 167 
the P value became non-significant due to the reduced sample size in the sub-group. 168 
 169 
 170 
 171 
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Statistical software 172 
All analyses were performed in Stata version 14.0 (StataCorp, College Station, TX, USA).  173 
 174 
Ethics approval 175 
All patients gave their informed, written consent to participate and the study was approved by the 176 
Cambridgeshire 2 Research Ethics Committee (reference number 07/H0308/163)  177 
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Results 178 
Maternal characteristics 179 
There were 878, 873, 854 and 591 women with steroid measurements at approximately mean (±SD) 180 
gestational ages 89 (±6), 143 (±3), 198 (±3) and 254 (±3) days, respectively. These are reported as 181 
measurements at 12, 20, 28 and 36 wkGA. Maternal characteristics of the women studied are summarized 182 
in Table 1. There were 29 cases of preterm PE, 160 cases of PE at term, 25 cases of preterm FGR and 165 183 
cases of FGR at term in the case-cohort for the main analysis. The sensitivity analysis included 12 cases 184 
of preterm PE, 123 cases of PE at term, 15 cases of preterm FGR and 125 cases of FGR at term, and 251 185 
women remained in the random sub-cohort. 186 
Patterns of cortisol, cortisone and cortisol to cortisone ratio throughout pregnancy  187 
In healthy women, cortisol and cortisone both increased as pregnancy progressed (Figs. 1a and 1b, 188 
respectively), whereas the cortisol to cortisone ratio showed an upward trend between 12 and 20 wkGA, 189 
plateaued until 28 wkGA and then fell at 36 wkGA (Fig. 1c). This pattern was similar in cases of FGR, 190 
but in PE, the cortisol to cortisone ratio started to decline at 28wkGA onwards (Fig. 1c).  191 
Associations between cortisol, cortisone and cortisol to cortisone ratio with PE and FGR 192 
There was a positive association between cortisol and cortisone in cases and controls, but for a given level 193 
of cortisol, the cortisone level was greater in cases of preterm PE at 28 wkGA and term PE at 36 wkGA 194 
(Figs. 2a and 2b, respectively). The cortisol to cortisone ratio was negatively associated with PE (Table 2 195 
and Fig. 3a) at 28wkGA and at 36wkGA, and the association was not materially affected by adjustment 196 
for maternal characteristics (Table 2). At 28 wkGA, the cortisol to cortisone ratio showed a negative 197 
association with the risk of preterm PE, term PE and preterm FGR. At 36 wkGA, the cortisol to cortisone 198 
ratio was also negatively associated with term PE but not with term FGR (Fig. 3a). The associations were 199 
broadly similar when the analysis was restricted to women who were not treated with steroids antenatally 200 
(Table 3). The association between the cortisol to cortisone ratio at 28 wkGA and preterm FGR was not 201 
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statistically significant at an alpha of 0.05, but there was no evidence of an interaction between the groups 202 
with and without antenatal steroid use (P value = 0.15 for the unadjusted analysis and P value = 0.13 for 203 
the adjusted analysis). Hence, the apparent loss of statistical significance likely reflected reduced 204 
statistical power due to a smaller sample size. 205 
Cortisol was negatively associated with the risk of term PE from 28 wkGA onwards (Fig. 3b) 206 
while the association between cortisone and the risk of term PE was negative in the first trimester and 207 
changed to positive in the third trimester (Fig. 3c). A similar association was also seen with cortisone and 208 
preterm PE (Fig. 3c), but not cortisol (Fig. 3b). The associations seen were stronger as pregnancy 209 
progressed for both the cortisol to cortisone ratio and cortisone in term and preterm PE (Figs. 3a and 3c). 210 
Cortisol was negatively associated with preterm FGR at 28 wkGA (Fig. 3b), but there were no clear 211 
associations between cortisone and preterm FGR (Fig. 3c), and, there was no clear association between 212 
cortisol or cortisone and term FGR (Figs. 3b and 3c).  213 
 214 
Cumulative incidence of PE according to cortisol to cortisone ratio 215 
There was a higher cumulative incidence of preterm PE and term PE for women in the lowest decile of 216 
cortisol to cortisone ratio compared with deciles 2-10 at the 28 and 36 wkGA measurements, respectively; 217 
approximately 2.2% and 11% cases in lowest decile vs 0.4% and 3% in deciles 2-10. For preterm PE, the 218 
curves started to deviate 2 weeks after the 28 wkGA measurement (Fig. 4a), and for term PE, the curves 219 
began to deviate at least a week after the 36 wkGA measurement (Fig. 4b). Similar results were obtained 220 
when women treated with steroids antenatally were excluded.  221 
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Discussion 222 
In this study, we found a clear negative association between the maternal serum cortisol to cortisone ratio 223 
and the risk of preterm and term PE. In women with term PE, the cortisol to cortisone ratio was 224 
significantly lower more than eight weeks before delivery. In term PE cortisol levels were lower at 28 225 
wkGA and cortisone levels were higher at 36 wkGA, and in preterm PE cortisone levels were higher at 28 226 
wkGA. These changes could represent higher 11βHSD2 activity or lower 11βHSD1 activity in women 227 
with PE, which occurs prior to the manifestation of clinical signs and symptoms. 228 
Multiple studies have shown lower placental 11βHSD2 activity after vaginal and cesarean 229 
delivery in women with PE and FGR (7-15), but our work and that of other studies investigating maternal 230 
blood and urine cortisol to cortisone ratio in women with established disease (18-20), suggests that 231 
maternal systemic 11βHSD2 activity is increased. The observation of reduced 11βHSD2 activity in 232 
placentas from women with PE may reflect general placental failure and local regulation of cortisol 233 
metabolism by the feto-placental unit which is independent of the mother. Aufdenblatten et al. (35) found 234 
that placental cortisol was almost completely inactivated in normotensive pregnancies, indicating an 235 
effective 11βHSD2 barrier from high levels of cortisol. This was in contrast to pregnancies with PE and 236 
low birth weight which had reduced placental 11βHSD2 activity and increased placental cortisol levels 237 
(31). Therefore, as 11βHSD2 is also expressed outside the placenta, the association between PE and FGR 238 
with a lower cortisol to cortisone ratio could be related to extra-placental 11βHSD2 activity, such as 239 
maternal renal 11βHSD2 (32,33).  240 
PE is frequently accompanied by renal dysfunction, but impaired renal function and hypertension 241 
in diseases outside of pregnancy have been associated with decreased renal 11βHSD2 expression and 242 
activity (34,35). Thus, maternal 11βHSD2 activity may increase as a compensatory response in PE, acting 243 
to reduce systemic cortisol. The systemic stress and inflammatory response which occurs in PE (36,37) 244 
may result in higher maternal cortisol secretion, which would suggest that 11βHSD2 activity increases to 245 
the extent that conversion of cortisol to cortisone exceeds cortisol secretion. However, cortisol secretion is 246 
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not definitively known to rise in PE, and there is limited evidence that cortisol itself stimulates 11βHSD2 247 
activity; exogenous corticosteroids have been shown to stimulate 11βHSD2 activity in bronchial 248 
epithelial cells (38), but the effects of cortisol on renal 11βHSD2 activity are not known, and since we 249 
observed a linear relationship between cortisol and cortisone levels in women with and without PE, it is 250 
likely that there are other factors responsible for stimulating 11βHSD2 action.  251 
Another explanation for the changes observed in cortisol and cortisone levels might be reduced 252 
11βHSD1 activity, as opposed to increased 11βHSD2 activity. There are studies showing reduced 253 
placental and chorionic 11βHSD1 activity in infants born SGA (birth weight less than the 10th percentile) 254 
(10,16), which could be a compensatory mechanism to reduce fetal cortisol exposure due to increased 255 
placental crossover of cortisol. But there are no studies in the literature which have studied activity of 256 
11βHSD1 in placentas from women with PE.  Furthermore, 11βHSD1 is present in the chorio-decidua 257 
(39,40) but it is unclear whether reduced 11βHSD1 activity at the feto-maternal interface would affect 258 
maternal cortisol and cortisone levels. Reduced maternal systemic 11βHSD1 activity is another possible 259 
explanation for the findings, but this is also yet to be investigated and would be an important area of 260 
future research. 261 
 Our study had several methodological strengths. First, to our knowledge, this is the first study to 262 
look at measurements of cortisol and cortisone in maternal serum preceding the onset of disease in both 263 
PE and FGR. Second, the case-cohort study design meant that we were able to study a large number of 264 
cases of PE and FGR, making this the largest study to date. Moreover, due to the large size of the cohort 265 
and the availability of serial ultrasound scans, we were able to confine our analysis of FGR to either 266 
infants which were extremely small for gestational age (<3rd percentile) or infants <10th percentile with 267 
other features indicating a likely pathological cause (preterm birth or reduced fetal growth velocity). 268 
Many other studies simply study small for gestational age infants (<10th percentile) and a large proportion 269 
of these will be healthy. The case-cohort design also meant that we were able to compare cases of PE and 270 
FGR with a population representative of the whole cohort. This is more likely to demonstrate a true 271 
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difference in participants with and without the outcomes studied than a case-control study, as in case-272 
control studies the comparison group are often healthy, and differences seen may just reflect the lack of 273 
other outcomes in the control group rather than the outcome of interest in cases. Details of the 274 
methodology underlying case-cohort studies and potential statistical and reporting issues are described by 275 
Sharp et al. (41).  276 
However, our study also has some limitations. Cortisol and cortisone were quantified as multiples 277 
of the median rather than SI units, so values cannot be directly compared with traditional measures of 278 
cortisol and cortisone in nmol/L. This is because the metabolomics assay was untargeted, and internal 279 
standards were not available for all metabolites. But, the quantification method is accurate and the ratio is 280 
unitless, so the results correctly reflect cortisol and cortisone levels measured using standard methods. 281 
Additionally, human cortisol secretion follows a circadian rhythm which was not accounted for in this 282 
study (42). But, Kosicka et al. (19) controlled for diurnal variation by taking early morning blood samples 283 
and drew the same conclusion that the maternal serum cortisol to cortisone ratio was reduced in PE. 284 
Cortisol secretion is influenced by external factors, including stress and anxiety (43). Although, we 285 
adjusted for some characteristics such as deprivation, marital and smoking status it was difficult to 286 
quantify any other external stresses that the study participants may have been experiencing. However, 287 
confounding by maternal stress is unlikely to have caused the associations as it would tend to be 288 
associated with increased rather than decreased cortisol levels. Furthermore, we also considered whether 289 
our findings could have been influenced by exogenous antenatal steroid use, and there were no clear 290 
differences in our results when these women were excluded. Whilst the association between the cortisol to 291 
cortisone ratio and preterm FGR at 28 wkGA where cases of antenatal steroid use had been excluded was 292 
not significant at an alpha of 0.05, the point estimates (OR) were within the 95% CIs of the analyses 293 
where they had not been excluded, and there was no evidence of an interaction between the ratio and 294 
exposure to steroids, thus the higher P values reflected reduced statistical power from a smaller sample 295 
size. 296 
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In conclusion, this study demonstrates that a lower maternal serum cortisol to cortisone ratio 297 
precedes the clinical manifestation of PE and preterm FGR by many weeks despite previous reports of 298 
elevated levels of placental 11βHSD2 in these conditions. Our observations implicate enhanced maternal 299 
11βHSD2 activity in the pathophysiology of PE. However, further investigation into the potential utility 300 
of the cortisol to cortisone ratio as a predictive marker of PE would be beneficial, given there is no current 301 
accurate predictive test for the condition. In addition, research into maternal and placental 11βHSD1 and 302 
11βHSD2 activity in women with PE and FGR and links to fetal and newborn cortisol metabolism would 303 
be useful in gaining a deeper understanding of the pathophysiology of the diseases. 304 
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Figure legends  437 
Figure 1. Mean with 95% confidence intervals for cortisol (a), cortisone (b) and the cortisol to 438 
cortisone ratio (c) at 12, 20, 28 and 36 wkGA in healthy pregnancies, women that developed PE and 439 
women who delivered a FGR infant. Cortisol and cortisone are reported as multiples of the median. 440 
Healthy pregnancies included women who did not have FGR, PE, gestational diabetes or spontaneous 441 
preterm delivery. Cases of PE were defined by the ACOG 2013 guidelines (24) and included all severe 442 
and non-severe, non-superimposed PE at term and all preterm PE. Cases of term FGR included severe 443 
SGA (birth weight <3rd customized percentile at term) and SGA with growth restriction (birth weight 444 
<10th customized percentile at term with reduced growth velocity of the abdominal circumference on 445 
serial ultrasound scans) without PE. Cases of preterm FGR included SGA with preterm delivery (birth 446 
weight <10th customized percentile and delivery prior to 37 completed wkGA) without PE.   447 
FGR, fetal growth restriction; MoM, multiples of the median; PE, pre-eclampsia; SGA, small for 448 
gestational age; wkGA, gestational age in weeks 449 
 450 
Figure 2. Scatter plots for cortisol vs cortisone at 28 wkGA in cases of preterm PE and controls (a) 451 
and 36 wkGA in cases of term PE and controls (b). Cortisol and cortisone are reported as multiples of 452 
the median. Cases of PE were defined by the ACOG 2013 guidelines (24) and included all severe and 453 
non-severe, non-superimposed PE at term and all preterm PE. Controls included women who did not have 454 
PE. Preterm delivery included pregnancies delivered < 37 wkGA and term delivery included pregnancies 455 
delivered ≥37 wkGA. For the measurement at 28 wkGA, the equation for the regression line in cases of 456 
preterm PE is y = 0.829 + 0.442 * x (P value for association = 0.01) and in controls is y = 0.526 + 0.469 * 457 
x (P value for association <0.001). The P value for interaction between preterm PE cases and controls at 458 
28 wkGA is 0.80. For the measurement at 36 wkGA, the equation for the regression line in cases of term 459 
PE is y = 0.909 + 0.612 * x (P value for association <0.001) and in controls is y = 0.887 + 0.479 * x (P 460 
value for association <0.001). The P value for interaction between term PE cases and controls at 36 461 
wkGA is 0.10.  462 
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MoM, multiples of the median; PE, pre-eclampsia; wkGA, gestational age in weeks  463 
 464 
Figure 3. Unadjusted odds ratios with 95% confidence intervals at 12, 20, 28 and 36 wkGA for term 465 
PE, preterm PE, term FGR and preterm FGR for (a) cortisol to cortisone ratio, (b) cortisol and (c) 466 
cortisone.  467 
Odds ratios are for cases referent to controls, associated with a one standard deviation higher cortisol to 468 
cortisone ratio, cortisol or cortisone value. Error bars represent the 95% confidence intervals. Cases of PE 469 
were defined by the ACOG 2013 guidelines (24) and included all severe and non-severe, non-470 
superimposed PE at term and all preterm PE. Cases of term FGR included severe SGA (birth weight <3rd 471 
customized percentile at term), SGA with growth restriction (birth weight <10th customized percentile at 472 
term with reduced growth velocity of the abdominal circumference on serial ultrasound scans), and all 473 
cases of PE were excluded from analyses of term FGR. Cases of preterm FGR included SGA (birth 474 
weight <10th customized percentile) with preterm delivery, and cases of preterm PE were excluded from 475 
analyses of preterm FGR. Preterm delivery included pregnancies delivered <37 wkGA and term delivery 476 
included pregnancies delivered ≥37 wkGA.  477 
FGR, fetal growth restriction; PE, pre-eclampsia; PTD, pre-term delivery; wkGA, gestational age in 478 
weeks  479 
 480 
Figure 4. Cumulative incidence of PE comparing the 1st decile of the cortisol to cortisone ratio with 481 
the 2nd-10th deciles of cortisol to cortisone ratio from 28 wkGA onwards in cases of preterm PE (a), 482 
and 36 wkGA onwards in cases of term PE (b). Figure 4a is reported in births per 1000 women and 4b 483 
is reported in births per 100 women.  Cases of PE were defined by the ACOG 2013 guidelines (24) and 484 
included all severe and non-severe, non-superimposed PE at term and all preterm PE. Preterm delivery 485 
included pregnancies delivered < 37 wkGA and term delivery included pregnancies delivered ≥37 wkGA. 486 
Delivery without PE was considered as the competing risk. 487 
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FGR, fetal growth restriction; PE, pre-eclampsia; wkGA, gestational age in weeks; PTD, pre-term 488 
delivery; SHR, Subhazard Ratio; CI, confidence interval489 
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Tables 490 
Table 1. Maternal characteristics and birth outcomes in women with healthy pregnancies, PE and 491 
FGRa. 492 
BMI, body mass index; FGR, fetal growth restriction; FTE, full-time education; MAP, mean arterial blood pressure; 493 
PE, preeclampsia; SD, standard deviation; wkGA, gestational age in weeks 494 
aData is expressed as mean (±SD) or n (%) with number of missing values below each characteristic. Where there is 495 
no missing category, data was complete.  496 
bWomen without FGR, PE, gestational diabetes or spontaneous preterm delivery.  497 
cDiagnosed according to ACOG 2013 guidelines (24) and divided into preterm (delivery <37 wkGA) and term 498 
outcomes (delivery ≥37 wkGA). Cases of PE include all severe and non-superimposed, non-severe PE at term and 499 
all preterm PE. 500 
 
Healthyb 
Preeclampsiac Fetal growth restrictiond 
Preterm  Term Preterm  Term 
N (% of case- cohort) 279 (30.2%) 29 (3.1%) 165 (17.9%) 25 (2.7%) 160 (17.3%) 
Maternal characteristics 
Age in years  30 (5) 28 (6) 30 (6) 30 (5) 30 (6) 
Age left FTE in years  
Missing (%) 
21 (4) 
1 (0.3%) 
20 (4) 
1 (3.4%) 
20 (4) 
5 (3.0%) 
20 (3) 
0 (0.0%) 
21 (4) 
3 (1.9%) 
Height in cm  165 (6) 162 (8) 164 (6) 165 (8) 165 (7) 
BMI  24.9 (4.7) 29.7 (5.9) 27.8 (6.3) 25.0 (4.9) 25.6 (5.0) 
Booking MAP  
Missing (%) 
78 (9) 
9 (3.2%) 
87 (10) 
0 (0.0%) 
83 (10) 
4 (2.4%) 
81 (9) 
1 (4.0%) 
79 (8) 
6 (3.8%) 
Married (%) 203 (72.8%) 22 (75.9%) 105 (63.6%) 16 (64.0%) 98 (61.3%) 
Smoker (%) 13 (4.7%) 1 (3.5%) 6 (3.6%) 3 (12.0%) 29 (18.1%) 
Alcohol (%) 10 (3.6%) 0 (0.0%) 7 (4.2%) 1 (4.0%) 7 (4.4%) 
Deprivation quartile (%) 
1 (lowest) 
2 
3 
4 (highest) 
Missing (%) 
 
60 (21.5%) 
81 (29.0%) 
57 (20.4%) 
71 (25.4%) 
10 (3.6%) 
 
8 (27.6%) 
2 (6.9%) 
14 (48.3%) 
5 (17.2%) 
0 (0.0%) 
 
41 (24.8%) 
38 (23.0%) 
40 (24.2%) 
38 (23.0%) 
8 (4.8%) 
 
3 (12.0%) 
6 (24.0%) 
6 (24.0%) 
9 (36.0%) 
1 (4.0%) 
 
42 (26.3%) 
27 (16.9%) 
41 (25.6%) 
43 (26.9%) 
7 (4.4%) 
White ethnicity (%) 
Non-white ethnicity (%) 
Missing (%) 
263 (94.3%) 
11 (3.9%) 
5 (1.8%) 
26 (89.7%) 
2 (6.9%) 
1 (3.4%) 
157 (95.2%) 
7 (4.2%) 
1 (0.6%) 
21 (84.0%) 
4 (16.0%) 
0 (0.0%) 
151 (94.4%) 
7 (4.4%) 
2 (1.3%) 
Characteristics of Delivery 
Mode of delivery (%) 
Vaginal 
Assisted vaginal 
Intrapartum caesarean 
Pre-labour caesarean 
Missing (%) 
 
140 (50.2%) 
58 (20.8%) 
54 (19.4%) 
25 (9.0%) 
2 (0.7%) 
 
7 (24.1%) 
0 (0.0%) 
3 (10.3%) 
19 (65.6%) 
0 (0.0%) 
 
36 (21.8%) 
51 (30.9%) 
55 (33.3%) 
22 (13.3%) 
1 (0.6%) 
 
6 (24.0%) 
5 (20.0%) 
1 (4.0%) 
13 (52.0%) 
0 (0.0%) 
 
94 (58.8%) 
30 (18.8%) 
16 (10.0%) 
20 (12.5%) 
0 (0.0%) 
Labour induced (%) 88 (31.5%) 7 (24.1%) 106 (64.2%) 4 (16.0%) 54 (33.8%) 
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dDivided into preterm (delivery <37 wkGA) and term outcomes (delivery ≥37 wkGA). Cases of FGR at term include 501 
severe SGA (birth weight <3rd customized percentile) and SGA with growth restriction (birth weight <10th 502 
customized percentile and reduced growth velocity of the abdominal circumference on serial ultrasound scans) 503 
without PE. Cases of preterm FGR include SGA (birth weight <10th customized percentile) with preterm delivery 504 
and without PE. Maternal characteristics and the summary of cortisol and cortisone levels were summarized for 505 
cases and healthy women due to the small overlap in cases in the random sub-cohort.506 
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Table 2. Unadjusted and adjusted ORs (95% CI) for PE and FGR by one standard deviation higher cortisol to cortisone ratio measured 507 
at different time points in pregnancy. *P value <0.05 **P value <0.001 508 
CI; confidence interval; FGR, fetal growth restriction; FTE, full-time education; OR, odds ratio; PE, preeclampsia; SGA, small for gestational age; wkGA, 509 
gestational age in weeks 510 
 511 
aDiagnosed according to ACOG guidelines (24) and divided into preterm (delivery <37 wkGA) and term outcomes (delivery ≥37 wkGA). Cases of PE include all 512 
severe and non-superimposed, non-severe PE at term and all preterm PE. 513 
bDivided into preterm (delivery <37 wkGA) and term outcomes (delivery ≥37 wkGA). Cases of FGR at term include severe SGA (birth weight <3rd customized 514 
percentile) and SGA with growth restriction (birth weight <10th customized percentile and reduced growth velocity of the abdominal circumference on serial 515 
ultrasound scans) without PE. Cases of preterm FGR include SGA (birth weight <10th percentile) with preterm delivery and without PE. 516 
cOdds ratios adjusted for antenatal height, age, BMI, marital status, ethnicity, smoking, age at leaving FTE, and deprivation. In the analysis of preterm 517 
preeclampsia, the adjustments for ethnicity and smoking were omitted since these variables predicted the outcome perfectly. 518 
dThe 36 wkGA measurements have not been analyzed for preterm outcomes. 519 
 520 
 521 
Approximate 
gestation of 
measurement 
(wkGA) 
Preeclampsiaa Fetal growth restrictionb 
Preterm Term Preterm Term 
Unadjusted  
OR  
(95% CI)  
Adjusted 
ORc 
(95% CI) 
Unadjusted 
OR 
(95% CI)  
Adjusted 
ORc 
(95% CI)  
Unadjusted 
OR 
(95% CI) 
Adjusted 
ORc 
(95% CI) 
Unadjusted 
OR 
(95% CI) 
Adjusted 
ORc 
(95% CI) 
12 
0.80 
(0.54-1.20) 
n/N=29/331 
0.68 
(0.44-1.04) 
n/N=29/331 
1.17 
(0.95-1.43) 
n/N=150/425 
1.14 
(0.92-1.41) 
n/N=150/425 
0.90 
(0.59-1.36) 
n/N=25/327 
0.93 
(0.60-1.45) 
n/N=25/327 
1.13 
(0.93-1.37) 
n/N=156/418 
1.15 
(0.94-1.41) 
n/N=156/418 
20 
0.68 
(0.43-1.08) 
n/N=25/331 
0.74 
(0.46-1.21) 
n/N=25/331 
1.02 
(0.83-1.24) 
n/N=152/433 
1.09 
(0.88-1.34) 
n/N=152/433 
0.74 
(0.47-1.16) 
n/N=25/331 
0.78 
(0.49-1.24) 
n/N=25/331 
1.01 
(0.83-1.24) 
n/N=156/425 
1.09 
(0.88-1.35) 
n/N=156/425 
28 
0.33 
(0.19-0.57)** 
n/N=24/328 
0.34 
(0.19-0.61)** 
n/N=24/328 
0.61 
(0.49-0.76)** 
n/N=151/430 
0.61 
(0.49-0.77)** 
n/N=151/430 
0.50 
(0.29-0.85)* 
n/N=21/325 
0.50 
(0.29-0.85)* 
n/N=21/325 
0.96 
(0.79-1.17) 
n/N=154/420 
0.96 
(0.78-1.19) 
n/N=154/420 
36d   
0.42 
(0.32-0.55)** 
n/N=134/409 
0.42 
(0.32-0.56)** 
n/N=134/409 
  
1.07 
(0.87-1.31) 
n/N=148/410 
1.14 
(0.92-1.41) 
n/N=148/410 
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Table 3. Unadjusted and adjusted ORs (95% CI) for PE and FGR by one standard deviation higher cortisol to cortisone ratio measured 522 
at different time points in pregnancy confined to women who were documented as not having received steroids antenatally. *P value <0.05 523 
**P value <0.001 524 
CI; confidence interval; FGR, fetal growth restriction; FTE, full-time education; OR, odds ratio; PE, preeclampsia; SGA, small for gestational age; wkGA, 525 
gestational age in weeks 526 
 527 
aDiagnosed according to ACOG guidelines (24) and divided into preterm (delivery <37 wkGA) and term outcomes (delivery ≥37 wkGA). Cases of PE included 528 
all severe and non-superimposed, non-severe PE. 529 
bDivided into preterm (delivery <37 wkGA) and term outcomes (delivery ≥37 wkGA). Cases of FGR at term include severe SGA (birth weight <3rd customized 530 
percentile) and SGA with growth restriction (birth weight <10th customized percentile and reduced growth velocity of the abdominal circumference on serial 531 
ultrasound scans) without PE. Cases of preterm FGR include SGA (birth weight <10th percentile) with preterm delivery and without PE. 532 
cOdds ratios adjusted for antenatal height, age, BMI, marital status, ethnicity, smoking, age at leaving FTE, and deprivation. In the analysis of preterm 533 
preeclampsia, the adjustments for ethnicity and smoking were omitted since these variables predicted the outcome perfectly. 534 
dThe 36 wkGA measurements have not been analyzed for preterm outcomes. 535 
Approximate 
gestation of 
measurement 
(wkGA) 
Preeclampsia Fetal growth restriction 
Preterm Term Preterm Term 
Unadjusted  
OR  
(95% CI) 
Adjusted OR 
(95% CI) 
Unadjusted 
OR  
(95% CI) 
Adjusted OR 
(95% CI) 
Unadjusted 
OR  
(95% CI) 
Adjusted 
OR  
(95% CI) 
Unadjusted 
OR  
(95% CI) 
Adjusted 
OR  
(95% CI) 
12 
0.70 
(0.37-1.33) 
n/N=12/248 
0.57 
(0.28-1.16) 
n/N=12/248 
1.15 
(0.91-1.44) 
n/N=113/331 
1.12 
(0.88-1.43) 
n/N=113/331 
1.00 
(0.59-1.68) 
n/N=15/251 
0.97 
(0.56-1.69) 
n/N=15/251 
1.15 
(0.93-1.42) 
n/N=120/328 
1.13 
(0.90-1.42) 
n/N=120/328 
20 
0.59 
 (0.26-1.32) 
n/N=9/253 
0.59 
(0.25-1.41) 
n/N=9/253 
1.02 
(0.81-1.29) 
n/N=113/339 
1.06 
(0.84-1.35) 
n/N=113/339 
0.91 
(0.52-1.61) 
n/N=15/259 
0.95 
(0.52-1.73) 
n/N=15/259 
1.00 
(0.79-1.26) 
n/N=119/335 
1.06 
(0.83-1.36) 
n/N=119/335 
28 
0.22 
(0.08-0.66)* 
n/N=9/246 
0.10 
(0.02-0.51)* 
n/N=9/246 
0.54 
(0.41-0.71)** 
n/N=112/330 
0.54 
(0.41-0.71)** 
n/N=112/330 
0.71 
(0.37-1.35) 
n/N=12/249 
0.71 
(0.35-1.41) 
n/N=12/249 
1.00 
(0.80-1.26) 
n/N=117/325 
0.98 
(0.77-1.25) 
n/N=117/325 
36   
0.42 
(0.31-0.57)** 
n/N=99/315 
0.41 
(0.30-0.57)** 
n/N=99/315 
  
1.09 
(0.86-1.39) 
n/N=114/320 
1.14 
(0.89-1.47) 
n/N=114/320 




